Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
Bionoid Pharma (OTC PINK:BINP) has announced the completion of its financial audits for fiscal years 2022 and 2023 by PCAOB-registered firm Olayinka Oyebola & Co. This development represents a key milestone in the company's commitment to financial transparency and regulatory compliance.
The audits were conducted according to Public Company Accounting Oversight Board (PCAOB) standards, ensuring the accuracy of Bionoid's financial reporting. The firm is also on schedule to complete the company's 2024 financial statements.
CEO Wayne Cockburn emphasized that this achievement aligns with Bionoid's expansion strategy, which focuses on strategic acquisitions and AI-driven growth initiatives. The company is particularly targeting revenue-generating e-commerce acquisitions and continues to integrate its AI Maverick platform for sustainable growth.
Bionoid Pharma (OTC PINK:BINP) ha annunciato il completamento delle sue revisioni finanziarie per gli anni fiscali 2022 e 2023 da parte della società registrata presso il PCAOB Olayinka Oyebola & Co. Questo sviluppo rappresenta una tappa fondamentale nell'impegno dell'azienda verso la trasparenza finanziaria e la conformità normativa.
Le revisioni sono state condotte secondo gli standard del Public Company Accounting Oversight Board (PCAOB), garantendo l'accuratezza della rendicontazione finanziaria di Bionoid. L'azienda è anche in programma per completare i bilanci finanziari del 2024.
Il CEO Wayne Cockburn ha sottolineato che questo risultato è in linea con la strategia di espansione di Bionoid, che si concentra su acquisizioni strategiche e iniziative di crescita guidate dall'AI. L'azienda sta particolarmente mirando ad acquisizioni di e-commerce che generano entrate e continua a integrare la sua piattaforma AI Maverick per una crescita sostenibile.
Bionoid Pharma (OTC PINK:BINP) ha anunciado la finalización de sus auditorías financieras para los años fiscales 2022 y 2023 por parte de la firma registrada en PCAOB Olayinka Oyebola & Co. Este desarrollo representa un hito clave en el compromiso de la empresa con la transparencia financiera y el cumplimiento regulatorio.
Las auditorías se realizaron de acuerdo con los estándares del Public Company Accounting Oversight Board (PCAOB), asegurando la precisión de los informes financieros de Bionoid. La firma también está en camino de completar los estados financieros de la empresa para 2024.
El CEO Wayne Cockburn enfatizó que este logro está alineado con la estrategia de expansión de Bionoid, que se centra en adquisiciones estratégicas e iniciativas de crecimiento impulsadas por IA. La empresa está especialmente enfocada en adquisiciones de comercio electrónico que generan ingresos y continúa integrando su plataforma AI Maverick para un crecimiento sostenible.
Bionoid Pharma (OTC PINK:BINP)는 PCAOB 등록 기업 Olayinka Oyebola & Co.에 의해 2022 및 2023 회계 연도의 재무 감사가 완료되었음을 발표했습니다. 이 발전은 회사의 재무 투명성과 규제 준수에 대한 약속의 중요한 이정표를 나타냅니다.
감사는 공공회사 회계감독위원회(PCAOB) 기준에 따라 수행되어 Bionoid의 재무 보고의 정확성을 보장했습니다. 이 회사는 또한 2024년 재무제표를 완료할 예정입니다.
CEO Wayne Cockburn은 이 성과가 전략적 인수와 AI 기반 성장 이니셔티브에 중점을 둔 Bionoid의 확장 전략과 일치한다고 강조했습니다. 회사는 특히 수익을 창출하는 전자상거래 인수를 목표로 하고 있으며, 지속 가능한 성장을 위해 AI Maverick 플랫폼을 계속 통합하고 있습니다.
Bionoid Pharma (OTC PINK:BINP) a annoncé l'achèvement de ses audits financiers pour les exercices fiscaux 2022 et 2023 par la société enregistrée auprès du PCAOB Olayinka Oyebola & Co. Ce développement représente une étape clé dans l'engagement de l'entreprise envers la transparence financière et la conformité réglementaire.
Les audits ont été réalisés conformément aux normes du Public Company Accounting Oversight Board (PCAOB), garantissant l'exactitude des rapports financiers de Bionoid. La société est également en bonne voie pour finaliser les états financiers de l'entreprise pour 2024.
Le PDG Wayne Cockburn a souligné que cette réalisation s'inscrit dans la stratégie d'expansion de Bionoid, qui se concentre sur des acquisitions stratégiques et des initiatives de croissance guidées par l'IA. L'entreprise cible particulièrement des acquisitions de commerce électronique génératrices de revenus et continue d'intégrer sa plateforme AI Maverick pour une croissance durable.
Bionoid Pharma (OTC PINK:BINP) hat den Abschluss seiner finanziellen Prüfungen für die Geschäftsjahre 2022 und 2023 durch die beim PCAOB registrierte Firma Olayinka Oyebola & Co. bekannt gegeben. Diese Entwicklung stellt einen wichtigen Meilenstein im Engagement des Unternehmens für finanzielle Transparenz und regulatorische Konformität dar.
Die Prüfungen wurden gemäß den Standards des Public Company Accounting Oversight Board (PCAOB) durchgeführt, um die Genauigkeit der finanziellen Berichterstattung von Bionoid sicherzustellen. Die Firma ist auch im Zeitplan, die finanziellen Abschlüsse des Unternehmens für 2024 abzuschließen.
CEO Wayne Cockburn betonte, dass dieser Erfolg mit der Expansionsstrategie von Bionoid übereinstimmt, die sich auf strategische Akquisitionen und KI-gesteuerte Wachstumsinitiativen konzentriert. Das Unternehmen zielt insbesondere auf umsatzgenerierende E-Commerce-Akquisitionen ab und integriert weiterhin seine AI Maverick-Plattform für nachhaltiges Wachstum.
- Successful completion of 2022 and 2023 financial audits by PCAOB-registered firm
- On track for timely completion of 2024 financial statements
- Strategic focus on revenue-generating e-commerce acquisitions
- None.
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by Olayinka Oyebola & Co., a PCAOB-registered firm. This milestone marks a significant step in Bionoid's commitment to financial transparency and regulatory compliance as the company continues executing its long-term growth strategy.
Olayinka Oyebola & Co. has worked diligently to complete the audits in accordance with Public Company Accounting Oversight Board (PCAOB) standards, ensuring the accuracy and integrity of Bionoid's financial reporting. The firm remains on track to finalize the company's 2024 financial statements as scheduled, further strengthening Bionoid's financial standing.
"The completion of our 2022 and 2023 audits is a critical achievement for Bionoid and underscores our dedication to financial accountability," said Wayne Cockburn, CEO of Bionoid Pharma, Inc. "As we continue our expansion through strategic acquisitions and AI-driven growth initiatives, maintaining strong financial governance remains a top priority. We appreciate the expertise and professionalism of Olayinka Oyebola & Co. and look forward to the timely completion of our 2024 financials."
Bionoid remains focused on scaling its operations through revenue-generating e-commerce acquisitions and the integration of its AI Maverick platform, positioning the company for sustainable growth and enhanced investor confidence.
About Bionoid Pharma, Inc.
Bionoid Pharma, Inc. is a forward-thinking health and wellness company dedicated to expanding revenue streams and brand presence through strategic acquisitions and advanced AI technology. Its proprietary AI Maverick platform enhances customer engagement and operational efficiency, supporting the company's mission to deliver innovative, AI-driven solutions for long-term growth.
Stay connected:
Website: BionoidPhama.com
OTC Markets: BINP
For further information, contact:
Wayne Cockburn, CEO
Phone: (905) 505-0770
Email: bionoidpharma@gmail.com
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the significance of BINP completing its 2022 and 2023 financial audits?
Who conducted Bionoid Pharma's (BINP) 2022-2023 financial audits?
What are BINP's current growth strategies according to the announcement?
When will BINP's 2024 financial audit be completed?
